Testing

Abbott Offers up Rapid Influenza Diagnostic

Feb 27, 2019

Influenza and its complications cause as many as 140,000 to 710,000 hospitalizations and 12,000 to 56,000 deaths annually in the U.S.

Another Reason to Update Your Biocompatibility Approach: EU MDRs

Jan 29, 2019

A chemist and biocompatibility expert offers the latest insights and predictions on medtech biocompatibility testing.

SyncThink Goes for Magic Leap to Get into AR

Jan 14, 2019

The Palo Alto, CA-based company will collaborate with Magic Leap, a specialist in augmented reality and spatial computer technology to bring its technology to an AR platform.

ArcherDx Seeking Broader Reach for Cancer Diagnostic

Jan 08, 2019

The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.

New Study Finds Discrepancies in Cervical Cancer Screening Rates

Jan 07, 2019

A study from Mayo Clinic researchers shows less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016, which is below the 81% screening compliance rate self-reported in the 2015 National Health Interview...

Veracyte Finds Ally in J&J for Early Lung Cancer Detection

Jan 03, 2019

The two companies will look at advancing the development and commercialization of diagnostic tests for early detection of the disease.

Consider the Most Probable Number Method for Bioburden Testing

Oct 22, 2018

The MPN method can be useful when traditional bioburden tests won’t work, but it must be clearly understood and carefully implemented.

7 Key Events That Solidified the Liquid Biopsy Market

Sep 19, 2018

Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.

Supplier Stories for the Week of August 5

Aug 09, 2018

Here’s what was new in the world of medical device suppliers during the week of August 5.

MDxHealth’s Liquid Biopsy Test Proven to Be Cost-Effective

Aug 02, 2018

Researchers found that SelectMDx, a test for prostate cancer, had a cost-savings of $1,694 per patient.

Keep You Informed